|Ms. Terrie J. Curran||President, CEO & Director||1.11M||N/A||1969|
|Mr. David A. Socks||Co-Founder & Director||58.78k||N/A||1975|
|Dr. Azmi Nabulsi M.D., M.P.H.||Co-Founder & COO||815.21k||N/A||1960|
|Ms. Molly Henderson CPA, MBA||Chief Financial & Business Officer||671.27k||N/A||1971|
|Mr. Aditya Kohli Ph.D.||Co-Founder||319.65k||N/A||1988|
|Mr. Anthony J. Guzzo||Chief Accounting Officer||468.27k||N/A||1973|
|Mr. Joseph Hand J.D.||Chief Administrative Officer||N/A||N/A||N/A|
|Mr. Lawrence Miller Esq., J.D.||General Counsel & Secretary||N/A||N/A||N/A|
|Mr. Tom Harris||Chief Development Sciences Officer||N/A||N/A||N/A|
|Dr. Eckhard Leifke M.D., Ph.D.||Chief Medical Officer||N/A||N/A||N/A|
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 December 2023 is 8. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 8; Compensation: 9.